Direct oral anticoagulants (DOACs) have become available as an alternative to warfarin
anticoagulation in non-valvular atrial fibrillation. The DOACs, dabigatran (a reversible direct …

ABSTRACT Introduction Direct oral anticoagulants (DOACs) have overtaken vitamin K
antagonists to become the most widely used method of anticoagulation for most indications …

Atrial fibrillation (AF) is a significant risk factor for stroke and peripheral thromboembolic
events (TEs). Preventing blood clots in the heart to reduce stroke and TE risk is a key goal of …

Warfarin has been the mainstay oral anticoagulant (OAC) medication prescribed for stroke
prevention in atrial fibrillation (AF) patients. However, warfarin therapy is challenging …

In recent years, the options for anticoagulant therapy have examined new direct oral
anticoagulants (DOACs) comprising direct thrombin inhibitors (dabigatran) and direct factor …

Oral anticoagulation therapy is transforming with the advent of the target specific oral
anticoagulants, particularly, the direct thrombin inhibitors and factor Xa inhibitors. These …

The introduction of direct oral anticoagulants (DOACs), such as dabigatran, rivaroxaban,
apixaban, edoxaban, and betrixaban, provides safe and effective alternative to previous …

Aims: Observational studies of various dose levels of direct oral anticoagulants (DOACs) for
patients with atrial fibrillation (AF) found that a high proportion of patients received a dose …

Anticoagulation for the prevention of stroke is an important aspect of the management of
atrial fibrillation. Novel anticoagulants including oral factor Xa inhibitors rivaroxaban and …

Atrial fibrillation (AF) continues to be a leading cause of cerebrovascular morbidity and
mortality resulting from cardioembolic stroke. Oral anticoagulation therapy has been shown …